MOLN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MO

Volume

678

Next Earnings

October 29th

Loading chart

MO

MOLNMolecular Partners AG American Depositary Shares

MOLN

Pay with—

Available Balance0.00

MO

Mkt Cap

$139.8M

Volume

678

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyMolecular Partners advanced its lead DLL3-targeting Radio-DARPin MP0712 to higher dose levels in Phase 1/2a trials with positive safety data, and selected CD70 as a new radiotherapy target for kidney cancer. The company reported a net loss of CHF 26.7 million in H1 2026 with cash reserves of CHF 67.9 million expected to fund operations into late 2027. Initial clinical data from MP0712 is anticipated in 2026 with efficacy data in 2027.GlobeNewswire Inc. · Aug 25, 2026

Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation SummitMolecular Partners AG announced that management will participate in a fireside chat at TD Cowen's 7th Annual Oncology Innovation Summit on May 27, 2026. The clinical-stage biotech company is developing DARPin therapeutics, a novel class of protein drugs, with lead candidate MP0712 progressing in Phase 1/2a trials with initial clinical data expected in 2026.GlobeNewswire Inc. · May 26, 2026

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317Molecular Partners announced Q1 2026 results with strong financial position (CHF 79 million cash runway until late 2027). The company initiated clinical studies on lead Radio-DARPin MP0712 targeting DLL3 for small cell lung cancer with four clinical sites open and initial data expected in 2026. MP0317 Phase 2 study for cholangiocarcinoma began with eight activated sites. New data demonstrated Radio-DARPins' amenability to multiple therapeutic isotopes, enabling an isotope-agnostic strategy.GlobeNewswire Inc. · May 12, 2026

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferencesMolecular Partners AG announced it will present its lead Radio-DARPin candidate MP0712 at three major scientific conferences in May 2026, including presentations on DLL3-targeting radiotherapy for small cell lung cancer and insights from first-in-human clinical trials.GlobeNewswire Inc. · May 4, 2026

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodelingMolecular Partners announced positive Phase 1 clinical data for MP0317, a tumor-localized CD40 agonist, published in Nature Cancer. The drug demonstrated favorable safety profile and proof-of-mechanism for tumor microenvironment remodeling in advanced cancer patients. An investigator-initiated Phase 2 trial in cholangiocarcinoma combining MP0317 with standard-of-care chemotherapy and anti-PD-L1 therapy is now enrolling patients across eight sites in France.GlobeNewswire Inc. · May 1, 2026

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General MeetingMolecular Partners AG held its Annual General Meeting on April 14, 2026, where shareholders approved all board proposals and elected Clare Fisher, an experienced pharmaceutical executive with over two decades of healthcare leadership, to the Board of Directors. The company also confirmed financial statements showing a net loss of CHF 57.9 million for 2025, bringing accumulated losses to CHF 257.3 million.GlobeNewswire Inc. · Apr 14, 2026

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of DirectorsMolecular Partners AG announced its Annual General Meeting scheduled for April 14, 2026, and nominated Clare Fisher, SVP of Global Business Development and M&A at BeOne Medicines, to join its Board of Directors. Current board member Steven H. Holtzman will not seek re-election after 12 years of service. Fisher brings over two decades of healthcare leadership experience in business development, M&A, and strategy from roles at companies including Takeda, Cubist Pharmaceuticals, and Blueprint Medicines.GlobeNewswire Inc. · Mar 23, 2026

Molecular Partners Reports Highlights and Financial Results for Full Year 2025Molecular Partners reported 2025 financial results with a net loss of CHF 61.7 million and cash position of CHF 93.1 million (runway until 2028). The company advanced its Radio-DARPin pipeline with MP0712 (DLL3-targeting) entering Phase 1/2a for SCLC, MP0726 (MSLN-targeting) progressing toward first-in-human imaging, and signed a development agreement with Eckert & Ziegler for multiple isotope capabilities. MP0317 (CD40 agonist) continues Phase 2 testing for cholangiocarcinoma, and MP0533 (T cell engager) showed encouraging data for AML treatment.GlobeNewswire Inc. · Mar 12, 2026

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare ConferenceMolecular Partners announced clinical development progress across its DARPin therapeutic pipeline, including initiation of a Phase 1/2a study for lead Radio-DARPin MP0712 targeting small cell lung cancer, with first patient dosing expected in Q1 2026. The company also reported ongoing Phase 2 trials for MP0317 in cholangiocarcinoma and MP0533 in acute myeloid leukemia, plus plans to nominate a lead Switch-DARPin candidate in H1 2026. As of December 31, 2025, the company holds CHF 93.1 million in cash, sufficient to fund operations until 2028.GlobeNewswire Inc. · Jan 11, 2026

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare ConferenceMolecular Partners AG, a clinical-stage biotech company developing DARPin therapeutics, will present its latest developments and 2025 outlook at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025.GlobeNewswire Inc. · Dec 18, 2025

to start trading

MO

MOLNMolecular Partners AG American Depositary Shares

MOLN

Pay with—

Available Balance0.00

Your PositionYou don't own any MOLN yet.

Related Tickers

Earnings